P
US10385376B2ActiveUtilityPatentIndex 67

21-hydroxylation of steroids

Assignee: SANOFI SAPriority: Oct 30, 2014Filed: Oct 29, 2015Granted: Aug 20, 2019
Est. expiryOct 30, 2034(~8.3 yrs left)· nominal 20-yr term from priority
Inventors:LATTEMANN CLAUSSTILLGER THOMASJANOCHA BERNDRASSER HANS-FALKRISSOM SEBASTIANANDERKO SIMONEBERNHARDT RITAHANNEMANN FRANK
C12P 33/06C12Y 118/01006C12Y 118/01002C12Y 114/9901C12Y 114/14C12N 15/52C12N 9/0095C12N 9/0087C12N 9/0042C07K 14/245C12P 33/00
67
PatentIndex Score
1
Cited by
26
References
14
Claims

Abstract

Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A process for the hydroxylation of the carbon atom 21 of a steroid, comprising the steps of:
 (a) providing a cell expressing:
 (i) a heterologous CYP21A2 protein or a functional variant thereof; 
 (ii) at least one heterologous electron transfer system capable of transferring electrons to CYP21A2; and 
 (iii) one or more chaperones facilitating folding of CYP21A2; and 
 
 (b) adding the steroid to the cell, 
 wherein the steroid is medrane or deltamedrane. 
 
     
     
       2. The process of  claim 1 , further comprising a step (c) of extracting the 21-hydroxylated steroid from the supernatant of the cell. 
     
     
       3. The process of  claim 1 , further comprising adding one or more cell permeabilizing agents to the cell after step (b). 
     
     
       4. The process of  claim 1 , wherein the cell is a resting cell. 
     
     
       5. The process of  claim 1 , wherein the cell is a prokaryotic cell or a eukaryotic cell. 
     
     
       6. The process of  claim 1 , wherein the at least one heterologous electron transfer system comprises:
 (a) a CYP21A2 reductase, and/or 
 (b) a ferredoxin reductase. 
 
     
     
       7. The process of  claim 1 , wherein the one or more chaperones are recombinantly expressed chaperones. 
     
     
       8. The process of  claim 1 , wherein the expression of at least one tryptophanase gene is reduced or abolished in the cell. 
     
     
       9. The process of  claim 1 , wherein the cell further expresses a heterologous gene encoding for an enzyme catalyzing a step in the heme biosynthesis pathway. 
     
     
       10. The process of  claim 1 , wherein the genes encoding for (i), (ii), and optionally (iii) are comprised in one or more expression cassettes which are integrated into the cell genome. 
     
     
       11. The process of  claim 5 , wherein the cell is an  E. coli  cell. 
     
     
       12. The process of  claim 5 , wherein the cell is a yeast cell. 
     
     
       13. The process of  claim 9 , wherein the heterologous gene encoding for an enzyme catalyzing a step in the heme biosynthesis pathway is a hemA gene. 
     
     
       14. The process of  claim 6 , wherein the at least one heterologous electron transfer system comprises an NADPH-dependent ferredoxin reductase and a ferredoxin.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.